Stryker SYK

Stryker Corporation is currently facing a mixed financial landscape with a 4.09% decline in total shareholder return over the past year. Despite this, Stryker launched new products, including the T2 Alpha Humerus Nailing System and the Mako RPS for Total Knee, aiming to bolster its offerings for over 150 million patients. The company has projected substantial free cash flow growth, estimating $3.5 billion in 2024 and $5 billion by 2027, although investor sentiment remains cautious with a Zacks Rank of #3 (Hold). This follows a series of strong quarterly performances, including an 11.4% year-on-year revenue increase in Q3 and a successful Q4 2025 that exceeded earnings expectations, which suggests a resilient market position amid revised price targets.